Format

Send to

Choose Destination
J Infect Dis. 2015 Feb 15;211(4):508-17. doi: 10.1093/infdis/jiu444. Epub 2014 Aug 27.

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.

Author information

1
Duke University, Durham, North Carolina.
2
University of Colorado School of Medicine, Aurora.
3
New York University, New York.
4
Frontier Science and Technology Research Foundation Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts.
5
Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts.
6
Military HIV Research Program, Bethesda, Maryland.
7
Department of Disease Control, Ministry of Public Health, Thailand.

Abstract

BACKGROUND:

Infant responses to vaccines can be impeded by maternal antibodies and immune system immaturity. It is therefore unclear whether human immunodeficiency virus type 1 (HIV-1) vaccination would elicit similar responses in adults and infants.

METHOD:

HIV-1 Env-specific antibody responses were evaluated in 2 completed pediatric vaccine trials. In the Pediatric AIDS Clinical Trials Group (PACTG) 230 protocol, infants were vaccinated with 4 doses of Chiron rgp120 with MF59 (n=48), VaxGen rgp120 with aluminum hydroxide (alum; n=49), or placebo (n=19) between 0 and 20 weeks of age. In PACTG 326, infants received 4 doses of ALVAC-HIV-1/AIDSVAX B/B with alum (n=9) or placebo (n=13) between 0 and 12 weeks of age.

RESULTS:

By 52 weeks of age, the majority of maternally acquired antibodies had waned and vaccine Env-specific immunoglobulin G (IgG) responses in vaccinees were higher than in placebo recipients. Chiron vaccine recipients had higher and more-durable IgG responses than VaxGen vaccine recipients or ALVAC/AIDSVAX vaccinees, with vaccine-elicited IgG responses still detectable in 56% of recipients at 2 years of age. Remarkably, at peak immunogenicity, the concentration of anti-V1V2 IgG, a response associated with a reduced risk of HIV-1 acquisition in the RV144 adult vaccine trial, was 22-fold higher in Chiron vaccine recipients, compared with RV144 vaccinees.

CONCLUSION:

As exemplified by the Chiron vaccine regimen, vaccination of infants against HIV-1 can induce robust, durable Env-specific IgG responses, including anti-V1V2 IgG.

KEYWORDS:

HIV-1; antibodies; infants; vaccine

PMID:
25170104
PMCID:
PMC4318918
DOI:
10.1093/infdis/jiu444
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center